| 王玉斌 陈文俊 郑维锷 张武 刘晓棠 王建化 李芙瑶 孙洪雨 王春妹.大剂量/常规剂量促红细胞生成素治疗癌性贫血的随机对比研究[J].实用中西医结合临床,2007,(2):1-2，4 |
| 大剂量/常规剂量促红细胞生成素治疗癌性贫血的随机对比研究 |
|
| |
| DOI： |
| 中文关键词: 癌性贫血 重组人促红细胞生成素 药物疗法 随机对比研究 |
| 英文关键词: Epoetin alfa Cancer Anemia random-control study |
| 基金项目:温州市科技局立项并资助课题(课题编号：Y2006A049) |
|
| 摘要点击次数: 673 |
| 全文下载次数: 277 |
| 中文摘要: |
| 目的：比较常规剂量重组人促红细胞生成素（rHuEPO）与大剂量rHuEPO治疗癌性贫血的疗效。方法：将血红蛋白（Hb）≤10.0 g/dL的癌性贫血病人随机分为常规剂量 rHuEPO组(A组：10 000U/次，qod，8周)与大剂量rHuEPO组（B组： 40 000U/次，qod×3次，然后1次/周×7周）,治疗不到8周者至Hb≥13.5 g/dL时停药。每周复查血常规， rHuEPO治疗2周后补充铁剂（力蜚能胶囊150mg 口服，1次/d）。结果：治疗开始的8周后评价疗效，A、B 2组有效率分别为55.7%、73.3%，P <0.05；在治疗的第2、4、8周，B组平均Hb水平高于A组，差异均有显著性，在治疗的第6周2组差异无显著性。与治疗前基础水平相比，B组在治疗的第2周Hb即显著升高[(10.15±1.1）对（9.30±0.91），P <0.05）]，而A组这种差异最早出现在第4周[（9.85±1.33)对(9.26±0.95)，P < 0.05）]；另外，治疗的第2、4、6、8周，Hb的平均水平B组均高于A组（P <0.05）。2组未见有明显的副作用发生。结论：大剂量rHuEPO治疗癌性贫血的疗效要好于常规剂量，升高Hb的速度也比常规剂量要快，副作用少且可以耐受。 |
| 英文摘要: |
| Objective：To compare the hemoglobin (Hb) response to common-dose erythromycin (group A)and high-dose erythromycin (group B),in anemic patients with cancer. Methods：Adults with solid tumors and baseline Hb 10g/dL were randomized to receive either EPO 40 000 U every 2 days three times (QOD×3),then once weekly (QW) or10 000U every 2 days (QOD) for up to 8 weeks. Observe the Hb level every week. Results : The proportion of patients achieving a 2.0g/dL Hb rise by week 8 was significantly higher in group B (73.3%) than in group A (55.7%), and group B patients achieved a 2.0g/dL Hb increase significantly earlier than group A (median, 33 days versus 45days). The mean increase in Hb from baseline was significantly higher at weeks 2，4，6 and the end of the study with high-dose erythromycin than with common-dose. There are no obvious side effects in two groups. Conclusion : The curative effect in guoup B is better than the guoup A and Hb in high-dose erythromycin group increase significantly earlier than those receiving common-dose.Side effects in Two groups could be toleration. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
